News related to
President

Over 80% Optimistic About Overseas Trade, Yet Tariffs and Costs Pose Key Hurdles

HONG KONG SAR – Media OutReach Newswire – 29 May 2026 – To support small and medium-sized enterprises (SMEs) in expanding into international markets, the Hong Kong Productivity Council (HKPC) and DHL Express Hong Kong (DHL) will co-host the “Blueprint for Global Expansion: Market Entry, Logistics & Risk Management” Forum on 12 June.

Amid an increasingly complex and rapidly evolving global supply chain landscape, the forum will delve into market strategies, logistics optimization, and risk management —equipping local businesses with the insights needed to navigate challenges and capture opportunities in global trade. As the first SME-focused forum jointly launched by HKPC and DHL, the initiative marks the beginning of a series of collaborative efforts to share practical expertise and support businesses in strengthening their international presence.

From Data to Strategy: Addressing the Three Key Barriers for SMEs Going Global
According to the latest quarterly “DHL Hong Kong Air Trade Leading Index (DTI)” survey, commissioned by DHL and conducted by HKPC, the primary challenges faced by enterprises expanding overseas are: “Complex tariff and customs clearance procedures” (23%), “High logistics and delivery costs” (20%) and “lack of local sales channels/ business partners” (12%). Despite these hurdles, over 85% of air traders remain neutral or positive about overseas trade prospects. In terms of readiness, 68% of respondents reported moderate confidence, while a further 18% showed high confidence, indicating a pragmatic and risk-aware approach among businesses pursuing global expansion.

In light of these findings, the forum will address the three critical dimensions of market, logistics, and risk management, offering professional guidance and targeted resources to help SMEs formulate immediate and actionable go-global strategies.

Andy Chiang, Senior Vice President and Managing Director, DHL Express Hong Kong and Macau, said, “DHL has long been committed to supporting SMEs in navigating the complexities of international trade. Through our GoTrade programme, we provide practical tools and expertise to help businesses manage cross-border logistics and customs processes more effectively. Our collaboration with HKPC focuses on equipping SMEs with actionable insights and strengthening their operational capabilities for global expansion. We look forward to continuing our partnership to deliver knowledge-sharing and networking opportunities that empower businesses to grow internationally with confidence.”

Three Thematic Sessions: A Comprehensive Global Expansion Blueprint for SMEs
The forum is specifically designed to address the pain points identified in the survey, featuring three expert speakers offering targeted insights:

￮ Professor Roy Liang TAN, Practitioner Professor of Management and Business Strategy at the HKU Business School will provide an in-depth analysis of how to assess target market maturity, avoid common pitfalls, and leverage government funding schemes to optimise financial planning — transforming the go-global vision into a concrete action plan.

￮ Ms Julian Tsoi, Director, Marketing Communications and Direct Sales, DHL Express Hong Kong, will share insights on how businesses can leverage global logistics networks and technology to enhance customs clearance efficiency and improve operational performance, while navigating the complexities of cross-border logistics and addressing common challenges in international expansion.

￮ Mr Kenneth POON, Assistant General Manager – Business Division at the Hong Kong Export Credit Insurance Corporation, will analyse export trade risks across different stages in emerging markets and guide enterprises on using credit insurance tools to guard against bad debts and strengthen financing capabilities.

Beyond expert presentations, the forum will feature interactive networking and Q&A sessions, allowing participants to exchange practical experiences directly with speakers and fellow SMEs, and explore business growth opportunities together.

Registration is now open. Seats are limited, first come first served!

“Blueprint for Global Expansion: Market Entry, Logistics & Risk Management” Forum

Date: 12 June 2026 (Friday)
Time: 3:00 PM – 5:00 PM
Venue: LG1, Future Manufacturing Hall, HKPC Building, 78 Tat Chee Avenue, Kowloon
Language: Cantonese and Putonghua
Registration Link: https://campaigns.hkpc.org/zh-hk/rsvp-blueprint-for-global-expansion

Hashtag: #HKPC

The issuer is solely responsible for the content of this announcement.

About Hong Kong Productivity Council

The Hong Kong Productivity Council (HKPC) is a statutory body established in 1967, dedicated to enhancing the productivity and competitiveness of Hong Kong enterprises through world-class applied R&D, innovative technology services, and integrated manufacturing solutions. As a market-oriented, international R&D organisation, HKPC leverages its deep expertise and extensive industry experience in key areas such as AI, advanced manufacturing, life and health technology, green technology and new energy to drive new industrialisation and support the growth of emerging and future industries.

HKPC focuses on addressing businesses challenges and industrial technology needs, promoting the full integration between technological and industrial innovation. Through technology transfer, product innovation, intellectual property protection and commercialisation of R&D outcomes, the Council fosters collaboration with the local business community as well as top global R&D institutions, delivering added value to industries and advancing the development of new productive forces. HKPC’s world-class R&D achievements have been widely recognised over the years, winning an array of local and overseas accolades, reinforcing Hong Kong’s role as an international innovation and technology centre and a smart city.

To help enterprises capitalise on Hong Kong’s strengths in international connectivity to expand into global markets, HKPC offers comprehensive overseas expansion services tailored to critical areas including product development, technology, manufacturing, and management, enabling businesses to successfully go global from Hong Kong.

HKPC is also committed to providing timely and practical support to SMEs and startups with timely and practical , assisting them in accessing Government funding programmes. Through its FutureSkills training initiatives, HKPC helps both industry and academia stay ahead in latest digital and STEM technologies, nurturing a future-ready talent pool for Hong Kong.

For more information, please visit HKPC’s website: www.hkpc.org/en.

DHL – The logistics company for the world

DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With approximately 389,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as “The logistics company for the world”.

DHL is part of DHL Group. The Group generated revenues of approximately 82.9 billion euros in 2025. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.

The logistics company for the world.

Another significant step towards the success of ICVAX®

HONG KONG SAR – Media OutReach Newswire – 27 May 2026 – Immuno Cure Group (“Immuno Cure“), headquartered at Hong Kong Science Park, is pleased to announce the inauguration of the research facility for its HIV therapeutic DNA vaccine (“ICVAX^®“) at the Center of International Innovation for Technology and Science (“CIITS”) located in Hetao, Shenzhen. The facility aims for the development and application of key technologies for the clinical research and commercialization of Immuno Cure’s ICVAX^®. ICVAX^® is developed by Immuno Cure with the aim of achieving antiretroviral therapy (“ART“)-free functional cure for HIV infection. This project is carried out in collaboration with Prof. Zhiwei CHEN, the Founding Director of the AIDS Institute of Li Ka Shing Faculty of Medicine, the University of Hong Kong (“HKU AIDS Institute“), and Prof. Hongzhou LU, President of the Third People’s Hospital of Shenzhen, in the capacity as advisors.

CIITS is a national-level achievement transformation platform co-built by Guangdong Province, Shenzhen Municipality, and Tsinghua University, and is located at the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone (“Hetao Co-operation Zone“). It is committed to building a world’s leading major technological innovation and industrialization platform with a global perspective. It focuses on key tracks including biomedicine, high-performance materials, and artificial intelligence (AI). It aims to aggregate global innovation resources, connect with leading enterprises, and conduct organized scientific research and achievement transformation to address national major strategic needs.

Since AIDS was first identified in 1981, 40.8 million people have died from HIV infection, with over 44.1 million people living with HIV globally. While antiretroviral therapy can effectively control HIV replication, it cannot cure the disease, highlighting the critical need for immunotherapies. Designed to enhance the host’s immune response, immunotherapies aim to achieve sustained viral control without lifelong ART, ultimately leading to complete viral suppression and functional cure. Immuno Cure’s proprietary innovative HIV therapeutic DNA vaccine, ICVAX^®, induces broad-spectrum, polyfunctional virus-specific T cells to achieve the ultimate goal of ART-free functional cure of HIV infection.

Immuno Cure completed the first-in-human Phase I clinical trial of ICVAX^® in November 2024, demonstrating excellent safety and promising immunogenicity. Two multi-center Phase II clinical trials—randomized, double-blind, and placebo-controlled—are scheduled to launch in Q2-2026 to evaluate the vaccine’s mechanism of action and efficacy. The trials will be conducted at Prince of Wales Hospital in Hong Kong, as well as eight top-tier hospitals in China, including the Shenzhen Third People’s Hospital, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing Youan Hospital affiliated to Capital Medical University, the Eighth People’s Hospital of Guangzhou, the Second People’s Hospital of Tianjin, the Sixth People’s Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center.

Notably, standardized testing systems for evaluating immunological and virological indicators are crucial for HIV vaccine clinical trials. However, the lack of domestic standard operating procedures (SOPs) for infectious samples in clinical trials hinders the clinical development and regulatory approval of novel infectious disease therapies like ICVAX^®. The mission of this research facility at CIITS is to establish an internationally aligned standardized clinical testing system for T-cell immunogenicity and viral reservoirs, as well as identify core biomarkers associated with vaccine efficacy — filling a domestic technical gap. Immuno Cure will offer the ICVAX^® Phase II clinical trial to facilitate the development of this standardized precision testing method for clinical sample analysis.

Dr. Xia JIN, CEO of Immuno Cure, stated, “I am delighted to be appointed to lead this key project of CIITS. I would also like to thank CIITS for the fully fitted modern laboratory space and the RMB10.0m funding support for this 2-year initial phase. My whole scientific team is committed to contributing diligently to the success of this project. I have no doubt that the development of a standardised testing regime would not only enhance the quality of our clinical trials for ICVAX^® but would also eventually be adopted as industry and national standards for the clinical translation of medicine for HIV/AIDS and other infectious diseases.

Renchen LIU, Executive Deputy Dean of Research Institute of Tsinghua University in Shenzhen and Director of CIITS, stated, “Warmest congratulations on the inauguration of the research facility for ICVAX^® at the CIITS. In the future, CIITS will continue to leverage its platform resources to implement full-chain incubation services. Project managers will provide service support throughout the entire project period, ensuring the smooth progress of the project through resource integration, talent recruitment and development, clinical collaboration, and achievement transformation. These efforts will safeguard the steady progress of the project.”

As the project advances, Immuno Cure’s ICVAX^® is positioned to become the world’s first therapeutic DNA vaccine to deliver an ART-free functional cure for HIV infection, bringing new hope to people currently living with HIV. In parallel, the standardized testing platform and collaborative innovation model developed through this effort will provide a scalable, replicable blueprint for R&D of novel therapies targeting other major infectious diseases. Together, these outcomes will strengthen the global competitiveness of biomedicine development in GBA and contribute to the development of national biosecurity capabilities and a more resilient public health system.

Hashtag: #ImmunoCure

https://immunocure.hk
https://www.linkedin.com/company/immuno-cure

The issuer is solely responsible for the content of this announcement.

About the Center of International Innovation for Technology and Science (“CIITS”)

Center of International Innovation for Technology and Science (CIITS), as the international headquarter of the Greater Bay Area National Center of Technology Innovation (GBA NCTI), is operated by Research Institute of Tsinghua University in Shenzhen (RITS). CIITS actively promotes the commercialization of technology and scientific advances with overseas and domestic innovation institutions and teams, as well as industry partners, focusing on areas such as biomedicine, advanced materials and artificial intelligence.

To learn more about CIITS, please follow the WeChat official account: gh_425f503135d5

About Immuno Cure

Immuno Cure is a clinical-stage biotechnology group headquartered at Hong Kong Science Park. Immuno Cure is committed to the R&D of innovative DNA vaccines and antibody immunotherapies for infectious diseases, inflammations, and cancers. Immuno Cure possesses two technologies: the “PD-1 Enhanced DNA Vaccine Platform” and the “Anti-Δ42PD1 Antibody”.

To learn more about Immuno Cure, please visit: www.immunocure.hk

By Nitya Chakraborty With the U.S. President Donald Trump himself downgrading the status of the four nation Quadrilateral Security Dialogue (QUAD), why is Indian government spending so much of its precious time on QUAD meetings? It is sheer wastage of time for the Prime Minister Narendra Modi as also Foreign Minister Dr. S Jaishankar. US […]

The article Trump Has Downgraded Status Of QUAD-India Should Not Waste Time On It appeared first on Latest India news, analysis and reports on Newspack by India Press Agency).

Dr. Chana Poomee, Honourary Chairman of TCMA and President of ASEAN Federation of Cement Manufacturers (AFCM), stated that today’s “National Milestone” reflects the power of collaboration at both national and international levels. The initiative is led by the United Nations Industrial Development Organization (UNIDO), in partnership with TCMA and key Thai government agencies, including the Department of Climate Change and Environment and the Department of Industrial Works, with financial support of CAD 8 million from the Government of Canada through Environment and Climate Change Canada (ECCC), to accelerate tangible greenhouse gas reductions in the cement and concrete sector.

TCMA, as the industry representative, serves as a central platform connecting stakeholders across the entire value chain, driving the implementation of the “Thailand 2050 Net Zero Cement and Concrete Roadmap.” This aligns with Thailand’s NDC 3.0 targets, strengthening industrial competitiveness, attracting green investment, and fostering sustainable economic growth.

“Decarbonization is not only a pressing challenge but also a strategic opportunity to enhance national competitiveness. The progress achieved under this project spans policy development, innovation, technology deployment, standards, and capacity building-key enablers that will accelerate the industry’s transition toward Net Zero”, Dr. Chana said.

A key technological advancement under the project is the introduction of the Mobile Carbon Capture Unit (MCCU) from CETRI, Canada. This advanced and flexible technology is designed for real-world industrial operations and will be piloted starting in June, rotating across cement plants of TCMA members in the SARABURI SANDBOX. The pilot aims to validate performance under diverse operational conditions and pave the way for large-scale industrial application.

“The deployment of MCCU in Thailand highlights the strength of international collaboration in bringing advanced technologies into real-world application. It accelerates learning-by-doing, validates technological performance, strengthens local technical capabilities, and reduces investment risks-laying a strong foundation for future scale-up”,
Dr. Chana added.

From an investment perspective, the development of technology-ready and standards-aligned projects enhances investor confidence, increases the attractiveness of green investment, and improves access to sustainable finance-key drivers in accelerating the industry’s transition to Net Zero.

TCMA continues to advance the industry under a “Collaborative Mindset-Action-Value,” promoting the systematic adoption of low carbon technologies, including low carbon cement innovations such as Limestone Calcined Clay Cement (LC³), Carbon Capture, Utilization and Storage (CCUS). These solutions not only reduce emissions but also improve efficiency, lower long-term costs, and strengthen global competitiveness.

At the regional level, TCMA is expanding its role through AFCM by fostering collaboration and advancing the AFCM Decarbonization Roadmap, which serves as a shared framework to reduce carbon emissions across ASEAN’s cement industry while enhancing regional technology, standards, and competitiveness.

“As President of the AFCM, TCMA is committed to driving ASEAN toward becoming a low carbon region by leveraging collaboration as a key mechanism to accelerate technology transfer, strengthen the industry capabilities, and unlock new regional economic opportunities”,
Dr. Chana said.

TCMA reaffirmed its commitment to strengthening collaboration and welcoming international support in both technology and finance to accelerate the transition toward a low carbon industry, while enhancing Thailand’s competitiveness on the global stage.

Hashtag: #TCMA #CementActionToNetZero #NetZero2050 #Decarbonization

The issuer is solely responsible for the content of this announcement.

This multi-party signing was officiated by Deputy Minister for Territorial and Urban Policy at Ministry of Land, Infrastructure and Transport of the Republic of Korea, Mr Jeong Eui-kyung; the Acting Secretary for Environment and Ecology, Miss Diane Wong; the Director of Electrical and Mechanical Services, Mr Poon Kwok-ying; and the Director-General of Investment Promotion of Invest Hong Kong (InvestHK), Ms Alpha Lau.

Spearheaded by Hyundai Motor Group, the MOU establishes a collaborative framework to build a comprehensive, self-sustaining hydrogen ecosystem in Hong Kong, targeted to be fully operational by the end of 2030. The collaboration will prioritise the development of waste-to-hydrogen technologies to convert landfill gas into clean energy, along with an immediate focus on piloting a liquefied hydrogen refuelling infrastructure. To enable full value chain integration, it also targets the deployment of customised hydrogen fuel cell commercial vehicles, including tour and airport shuttle buses.

Through facilitating public-private partnerships and inter-governmental collaboration, InvestHK is supporting Hyundai Motor Group and its partners to implement go-to-market strategies aligned with the shared vision for hydrogen ecosystem building.

This partnership will also position Hong Kong as a strategic base for Hyundai Motor Group’s hydrogen business expansion across the Asia-Pacific region.

Miss Wong said, “This collaboration marks a significant milestone in developing tangible, on-the-ground hydrogen applications to accelerate the green transition towards carbon neutrality. By combining Korea’s world-class technological capabilities with Hong Kong’s strategic urban context, Hong Kong could serve as an exceptional international demonstration platform for showcasing green and low-carbon technologies. If these cutting-edge innovations could be applied and scaled up successfully here, it will serve as a positive model and provide highly viable options for reference by modern cities worldwide.”

Ms Lau said, “Today’s multi-party signing is both a landmark moment for Hong Kong’s green economy and a clear signal that the city’s hydrogen ecosystem is gaining real traction. Over the past three years, InvestHK has helped leading hydrogen enterprises establish themselves in Hong Kong, several of which have since listed on the Hong Kong Stock Exchange, raising over $2.5 billion in total. For businesses with global green ambitions, Hong Kong is where business growth takes shape.”

Executive Vice President and Head of Energy & Hydrogen Policy Sub-Division at Hyundai Motor Group, Mr Seung Kyu-shin, said, “This MOU was signed as Hyundai Motor Group’s commitment to advancing Hong Kong’s proactive hydrogen policies and driving the acceleration of its hydrogen ecosystem utilising the Group’s hydrogen business capability and experience. Starting with Hong Kong, we look forward to expanding our collaboration and business opportunities across the broader Asia-Pacific hydrogen market.”

Partners entering into this MOU include Hyundai Motor Company and Hyundai Engineering & Construction from Hyundai Motor Group, China Inspection Co Ltd, Chun Wo Bus Services Limited, Chun Wo Construction & Engineering Company Limited, Jiangsu Guofu Hydrogen Energy Equipment Co Ltd, JEA ENG, Templewater Limited, the Hong Kong and China Gas Company Limited, and Veolia Hong Kong Holding Limited.

This multi-party, long-term collaboration is set to establish a robust, end-to-end hydrogen industry chain – spanning production, storage, transportation, refuelling and utilisation.

New energy is vital to Hong Kong’s Climate Action Plan 2050 and the national dual-carbon goals. As set out in the Chief Executive’s 2025 Policy Address, Hong Kong will establish public hydrogen filling facilities on Hong Kong Island and in Kowloon, press ahead with more hydrogen trial projects, and develop the GBA Hydrogen Corridor in collaboration with Guangdong Province. The Hong Kong Special Administrative Region Government is actively advancing hydrogen development through technological innovation, talent cultivation, ecosystem building, and regional co-ordination. To date, over 30 hydrogen trial projects have been greenlit, paving the way not only for decarbonisation targets, but also for unlocking new quality productive forces for green economic growth.
Hashtag: #InvestHK

The issuer is solely responsible for the content of this announcement.

About InvestHK

Invest Hong Kong (InvestHK) is the investment promotion agency of the Government of the Hong Kong Special Administrative Region (HKSAR).

The New York-founded company, led by Shayne Coplan, is seeking to open discussions around whether event-based contracts can be permitted under Japan’s financial and digital-asset framework rather than treated purely as gambling. The move comes as prediction markets draw heavier institutional interest, stronger trading volumes and sharper scrutiny from regulators over consumer protection, market integrity and the legal boundary between betting and derivatives.

People familiar with the matter said the company’s Japan strategy is at an early stage and would require engagement with officials, lawmakers and industry participants before any formal market entry. Japan does not have a dedicated framework for cash-based prediction markets, leaving platforms that allow users to trade on political, economic, sports or cultural outcomes exposed to uncertainty under gambling and financial laws.

Polymarket allows users to buy and sell contracts tied to the outcome of real-world events, with prices reflecting market-implied probabilities. Its markets have covered elections, central bank decisions, geopolitical events, sports, entertainment and cryptocurrency milestones. The platform gained global visibility during the 2024 US presidential election cycle, when trading volumes surged and its odds were widely cited as an alternative gauge of political sentiment.

Japan would offer Polymarket a large, sophisticated retail market with deep participation in equities, foreign exchange and digital assets. The country has also built one of the world’s more structured crypto regulatory regimes, requiring registration for crypto-asset exchange service providers and imposing rules on custody, anti-money laundering controls and customer protection. That framework may give the company a potential route for engagement, although prediction markets remain a separate and more politically sensitive category.

The company’s global push has accelerated after a period of regulatory pressure in the United States. Polymarket settled a case with the Commodity Futures Trading Commission in 2022 after being accused of offering off-exchange event-based binary options without proper registration. It blocked US users for several years before moving to rebuild a domestic regulatory path through acquisitions and licensing efforts. Its purchase of a derivatives exchange and clearinghouse gave it a route to pursue compliant US operations.

Institutional backing has also strengthened its position. Intercontinental Exchange, the parent of the New York Stock Exchange, agreed to invest up to $2 billion in Polymarket in a deal that valued the business at about $8 billion before the transaction. The partnership gave Polymarket a powerful market infrastructure ally and signalled that event-driven data may have value beyond retail speculation, particularly for investors seeking real-time sentiment around political, economic and corporate developments.

Competition is intensifying. Kalshi, a regulated US prediction market operator, has expanded rapidly by framing event contracts as financial instruments under commodities law. Its growth has triggered legal disputes with state regulators, some of whom argue that sports and election-linked contracts resemble gambling products. That debate is likely to influence Japan’s assessment of whether prediction markets can be supervised as finance, gaming, information markets or a hybrid category.

Polymarket’s Japan plan faces several obstacles. Gambling is tightly restricted, with permitted activity largely confined to state-authorised sectors such as horse racing, bicycle racing, motorboat racing, lotteries and pachinko-linked structures. Online betting carries heightened enforcement risks, and any product involving wagers on uncertain outcomes would need careful legal classification. A crypto-funded model could add further complexity because regulators would need to examine custody, settlement, identity checks, sanctions screening and investor suitability.

Supporters of prediction markets argue that they create useful public signals by aggregating dispersed information into tradable prices. Traders who believe a market is mispriced can buy or sell contracts, pushing prices closer to collective expectations. That model has appealed to political analysts, hedge funds, economists and technology investors seeking faster indicators than polls, surveys or conventional research.

Critics counter that thin liquidity, anonymous participation, insider access and coordinated trading can distort outcomes. Questions have intensified around markets linked to sensitive events, where participants may possess non-public information or where the existence of a market could create troubling incentives. Japan’s regulators are likely to examine whether surveillance systems, position limits, disclosure rules and dispute-resolution mechanisms are strong enough to reduce those risks.

By Nitya Chakraborty The joint declaration made by Chinese President Xi Jinping and the visiting Russian President Vladimir Putin after their summit in Beijing on May 20 has major ramifications on the global geopolitics in the context of the present unilateral actions of the U.S. President Donald Trump including the launching of war against Iran […]

The article China-Russia Joint Declaration From Beijing Summit Puts More Pressure On Trump appeared first on Latest India news, analysis and reports on Newspack by India Press Agency).